Close
Achema middle east
swop processing & packaging

Canadian companies complete handover of drugs rights

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Nuvo Pharmaceuticals has acquired the rights covering more than 20 drugs from fellow Canadian company Aralez Pharmaceuticals.

With the deal, announced by Nuvo on Monday, December 31, Nuvo now owns Aralez’s Canadian speciality pharmaceutical business. This unit includes anti-inflammatory drug Cambia (diclofenac potassium), which is under licence from Depomed, as well as Blexten (bilastine), an antihistamine, licensed from Faes Farma.

Aralez’s pharma business also includes the Canadian distribution rights to Resultz (isopropyl myristate), a head lice treatment, which it licenses from Piedmont Pharmaceuticals.

Nuvo said this part of the deal will allow the company to acquire and launch additional commercial products in Canada.

Nuvo has also acquired the worldwide rights and royalties from licensees for arthritis drug Vimovo (naproxen and esomeprazole magnesium) and Yosprala (aspirin and omeprazole), a treatment for reducing the risk of further heart problems in people with such difficulties, among other things.

In August 2018, the companies announced that they were in talks on the potential acquisition.

In the recent announcement, Nuvo confirmed that the agreed payment to Aralez is $110 million less a $4.4 million deposit previously paid “and subject to certain working capital and indebtedness adjustments”.

Jesse Ledger, Nuvo’s president and CEO, said that the close of the transaction “positions Nuvo as one of the premier speciality pharmaceutical companies in Canada”.

In its own statement, Aralez explained that after deciding to sell its main operating businesses, the company conducted a court-supervised sale and auction process as part of independent Canadian and US restructuring proceedings. The Ontario Superior Court of Justice and the US Bankruptcy Court ultimately approved the sales to Nuvo in December 2018.

Financing for the acquisition was provided by Deerfield Management Company, which has offices in the US, China and Switzerland.

Latest stories

Related stories

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »